CASI PHARMACEUTICALS, INC. Retained Earnings
CASI PHARMACEUTICALS, INC. (CASIF) had Retained Earnings of -$748.13 million as of 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-05-15
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$748.13M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$700.08M.
- 2023-12-31: Retained Earnings (Accumulated Deficit) -$660.82M.
- 2022-12-31: Retained Earnings (Accumulated Deficit) -$637.16M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2025-12-31 | -$748.13M 20-F · filed 2026-05-15 |
| 2024-12-31 | -$700.08M 20-F · filed 2026-05-15 |
| 2023-12-31 | -$660.82M 20-F · filed 2025-03-31 |
| 2022-12-31 | -$637.16M 20-F · filed 2024-03-28 |
| 2021-12-31 | -$605.64M 20-F · filed 2023-04-26 |